After a positive Cologuard: how the follow-up colonoscopy is billed

The stool test looks large on the fee schedule and costs an Original Medicare patient nothing. Medicare's laboratory fee schedule lists $508.87 for the multi-target stool DNA test (CPT 81528) and $15.92 for a fecal immunochemical test (CPT 82274), a gap of 31.96 to 1. Yet an Original Medicare patient owes $0 for either one when the provider accepts assignment. The money question sits one step later, in how the colonoscopy gets classified: as the second half of a screening, or as a stand-alone diagnostic procedure with a deductible and coinsurance.

That classification is made on the claim, by codes and modifiers, before any person decides what you owe. Under Original Medicare, a diagnostic label puts the hospital outpatient example below at $224.52 for a colonoscopy where nothing is removed, after the $283.00 deductible is already met. With the screening label, the same procedure costs $0. For a colonoscopy that removes a polyp, the gap in 2026 is $72.80, and the Medicare schedule shrinks it toward nothing by 2030. The rules below say which label the law expects and where each rule stops.

Every layer a follow-up can bill

One screening-then-colonoscopy episode arrives as several statements from different senders, and each follows its own fee schedule. A person who sees one unexpected balance usually has the right rule and the wrong statement in hand. The layers below are listed in the order the care happens; the last column says what this guide prices and what it leaves to a sibling guide.

Layers follow the federal FAQ list of items integral to a screening colonoscopy (consultation, bowel-prep medication, anesthesia, polyp removal, polyp pathology) and the Medicare payment systems named in Claims Processing Manual chapter 18, section 60.1. Checked November 3, 2026. No amounts are added across layers on this page, because no source publishes a combined total. Physician amounts are for Michigan Locality 01 and facility amounts are national unadjusted rates; another locality and a hospital's wage index move every dollar figure, though not the percentages.

Three of those topics already have guides here. The preventive visit rules, including the question of a pathology bill on a screening polyp, are in why a free preventive visit came with a bill, and the Medicare cost-sharing mechanics for hospital outpatient procedures are in what Medicare patients pay for an outpatient procedure. Pathology on a removed polyp is a separate bill with its own rules in the pathology bill guide. This guide stays with the narrower question that those pages do not answer: what changes on each layer when the colonoscopy was triggered by a positive stool test.

Stool and blood test rates for 2026

The Clinical Laboratory Fee Schedule file for the fourth quarter of 2026 (26CLABQ4) lists the rates below for the tests that start the chain. The Medicare Claims Processing Manual identifies CPT 81528 as the code for the Cologuard multi-target stool DNA test, which replaced HCPCS G0464 on January 1, 2016. Each one is the amount Medicare pays the laboratory for the code. It is a different number from the laboratory's own charge and from what a commercial plan pays under its contract, and none of it is a patient price.

Source: CMS Clinical Laboratory Fee Schedule public use file 26CLABQ4 (PUF_CLFS_CY2026_Q4V1), fourth quarter 2026, effective date 20260101 for every row shown. Descriptors are the file's extended descriptions. Checked November 3, 2026. Medicare payment rates, not your bill and not a cash price.

Three differences in the table are worth knowing before a statement arrives. The first is the spread between the two stool-based approaches: $508.87 for the DNA-plus-hemoglobin test against $15.92 for the hemoglobin-only immunoassay. The second is inside the immunoassay family. The file lists CPT 82274 at $15.92 and the screening code G0328 at $18.05, a difference of $2.13, and the older guaiac screening code 82270 at $4.38, which is $13.67 below G0328. The third is the second multi-target code, 0464U, at $591.92, which is $83.05 above 81528. Its descriptor names a different set of DNA markers (methylated markers plus a reference marker and a protein marker for fecal hemoglobin) from the 10-marker panel in the 81528 descriptor, so the two codes describe different assays and are priced as such.

The last row is the odd one. The blood-based screening code G0327 has a rate of $0.00 and the indicator L. The file's read-me describes the indicator column only as the "national or local pricing indicator," and a zero rate beside an L is how the file shows a code that has no national amount, so no dollar figure can be printed for it here. Medicare's Claims Processing Manual, chapter 18, section 60.1, says G0327 is paid under the clinical laboratory fee schedule for dates of service on or after January 19, 2021, and the fee file simply does not carry a national rate for it in this quarter.

What the patient owes on these lines is a separate question from the rate. Medicare.gov says you pay nothing for a multi-target stool DNA test or a fecal occult blood test if your provider accepts assignment, and its costs page lists $0 for covered clinical laboratory services. A private plan treats a covered stool test as a screening service too, but a plan sets its own allowed amount, so the $508.87 figure is a benchmark for order of magnitude and nothing more. The fuller table of laboratory codes, including how a code's description can change the rate, is in the guide to the clinical laboratory fee schedule.

One coding detail connects this table to the colonoscopy rules that follow. The manual sentence that sets up the Medicare follow-on route names three stool-based tests: 82270, G0328 and 81528. It does not name 82274, 0464U or G0327. That does not tell you a claim with one of those codes will be denied, because the regulation text discussed next is broader than the manual's list. It only means the manual's list and the fee file's list differ, and a statement whose lab code is not on the manual's list is a fair thing to raise with the contractor rather than assume away.

Dated rules for the follow-up colonoscopy

The rules arrived in stages between 2010 and 2026, from several different sources, and the dates are the part that gets mangled. The table gives each rule with the source that states it and the date that source attaches to it. Where two sources give different dates for what looks like one change, each date sits in its own row.

Sources: eCFR 45 CFR 147.130 and 42 CFR 410.37 (versions dated October 28, 2026); U.S. Code, 42 U.S.C. 1395l, Office of the Law Revision Counsel release current through Public Law 119-136 (October 22, 2026); FAQs About Affordable Care Act Implementation Part 51 (January 10, 2022); USPSTF colorectal cancer screening recommendation (May 18, 2021); CMS Claims Processing Manual chapter 18 (Rev. 13709, issued 04-02-26) and National Coverage Determination 210.3. All checked November 3, 2026.

The private-plan row rests on one FAQ. The question and its full answer read:

Q7: Are plans and issuers required to cover, without the imposition of any cost sharing, a follow-up colonoscopy conducted after a positive non-invasive stool-based screening test or direct visualization test (e.g., sigmoidoscopy, CT colonography)?

Yes. A plan or issuer must cover and may not impose cost sharing with respect to a colonoscopy conducted after a positive non-invasive stool-based screening test or direct visualization screening test for colorectal cancer for individuals described in the USPSTF recommendation. As stated in the May 18, 2021 USPSTF recommendation, the follow-up colonoscopy is an integral part of the preventive screening without which the screening would not be complete. The follow-up colonoscopy after a positive non-invasive stool-based screening test or direct visualization screening test is therefore required to be covered without cost sharing in accordance with the requirements of PHS Act section 2713 and its implementing regulations.

Q8 supplies the start date. Plans and issuers "must provide coverage without cost sharing for plan or policy years beginning on or after May 31, 2022," because the Departments treat the May 2021 recommendation as issued on May 31, 2021. For a plan that runs on the calendar year, the first plan year that begins on or after that date starts January 1, 2023. A plan with a July 1 plan year was bound from July 1, 2022. A follow-up colonoscopy in the 2022 plan year of a calendar-year plan therefore fell before the rule applied to that plan, which matters if an old statement is being disputed.

The Medicare rows have a wrinkle that a casual reading of one source misses. The current regulation, 42 CFR 410.37(k), is dated January 1, 2025 and reads in full: "A complete colorectal cancer screening. Effective January 1, 2025, colorectal cancer screening tests include a follow-on screening colonoscopy after a Medicare covered non-invasive stool-based colorectal cancer screening test or blood-based biomarker colorectal cancer screening test returns a positive result. A follow-on screening colonoscopy in the context of a complete colorectal cancer screening is not subject to the frequency limitations for colorectal cancer screening in paragraphs (g)(2) or (3) of this section." The stool-based follow-on route is older than that text. The Claims Processing Manual, section 60.2, applies it to dates of service on or after January 1, 2023, and the National Coverage Determination's revision history for January 2023 describes the change as expanding the definition of screening tests "to include a follow-on screening colonoscopy after a Medicare covered non-invasive stool-based test returns a positive result." The 2025 text added the blood-based test. The two documents also word the frequency point differently. The regulation names paragraphs (g)(2) and (g)(3), the 24-month and 48-month intervals, while the manual says the frequency limitations for G0105 and G0121 "shall not apply" for the follow-on route.

The same regulation holds the rule for tissue removal. Paragraph (j) says: "Effective January 1, 2022, colorectal cancer screening tests include a planned screening flexible sigmoidoscopy or screening colonoscopy that involves the removal of tissue or other matter or other procedure furnished in connection with, as a result of, and in the same clinical encounter as the screening test." That sentence is why a polyp found during a screening does not turn the whole procedure into a diagnostic one for Medicare's purposes. It still carries a coinsurance, but a reduced and shrinking one.

Where the private-plan rule stops

The sentence "must cover and may not impose cost sharing" has edges, and each edge is in the text of the regulation or the FAQ. They matter because a statement that looks wrong may be a correct application of a limit, and a statement that looks routine may be a violation.

The rule reaches only plans that are not grandfathered. The FAQ opens its preventive services section by saying section 2713 and its regulations "require non-grandfathered group health plans and health insurance issuers offering non-grandfathered group or individual health insurance coverage" to cover the listed services without cost sharing, and 45 CFR 147.130(d) points to section 147.140 for the point that these rules do not apply to grandfathered plans. A plan's summary of benefits or its annual notice says whether it claims grandfathered status.

The rule follows the age bands of the recommendation. The regulation covers items "that have in effect a rating of A or B." The Task Force rates screening at ages 50 to 75 as A and at ages 45 to 49 as B. It rates screening at ages 76 to 85 as C, with the recommendation that clinicians "selectively offer" it. Q7 applies "for individuals described in the USPSTF recommendation." For a person aged 76 to 85, the federal rule does not itself require the waiver, and the plan's own benefits decide. That is a different result from Original Medicare, which covers its multi-target stool DNA and blood-based tests through age 85 and lists no minimum age for a screening colonoscopy on its colonoscopy page.

The rule names two kinds of first test. Q7 speaks of a "positive non-invasive stool-based screening test or direct visualization screening test." The January 2022 document does not mention blood-based tests. A follow-up after a positive blood-based test is therefore not addressed by Part 51 at all, and the plan's written terms are the place to look.

Three provisions of 45 CFR 147.130 narrow what a plan must waive. Each is quoted in full here.

• Out-of-network providers. Paragraph (a)(3)(i) reads: "Subject to paragraphs (a)(3)(ii) and (iii) of this section, nothing in this section requires a plan or issuer that has a network of providers to provide benefits for items or services described in paragraph (a)(1) of this section that are delivered by an out-of-network provider, or precludes a plan or issuer that has a network of providers from imposing cost-sharing requirements for items or services described in paragraph (a)(1) of this section that are delivered by an out-of-network provider." Paragraph (a)(3)(ii) adds the exception: "If a plan or issuer does not have in its network a provider who can provide an item or service described in paragraph (a)(1) of this section, the plan or issuer must cover the item or service when performed by an out-of-network provider, and may not impose cost sharing with respect to the item or service." Paragraph (a)(3)(iii) concerns coronavirus preventive services only.
• Reasonable medical management. Paragraph (a)(4) reads: "Nothing prevents a plan or issuer from using reasonable medical management techniques to determine the frequency, method, treatment, or setting for an item or service described in paragraph (a)(1) of this section to the extent not specified in the relevant recommendation or guideline. To the extent not specified in a recommendation or guideline, a plan or issuer may rely on the relevant clinical evidence base and established reasonable medical management techniques to determine the frequency, method, treatment, or setting for coverage of a recommended preventive health service."
• Treatment. The second sentence of paragraph (a)(5) reads: "A plan or issuer may impose cost-sharing requirements for a treatment not described in paragraph (a)(1) of this section, even if the treatment results from an item or service described in paragraph (a)(1) of this section." The first sentence of (a)(5) says the section does not stop a plan from covering more than the recommended services or from denying coverage for items and services the Task Force and the advisory committee do not recommend.

The third provision explains the line between the screening and what comes after it. A colonoscopy that completes the screening carries no cost sharing; care for a condition the colonoscopy finds is treatment, and the plan may price it under its ordinary benefits. The FAQ's list of items integral to a colonoscopy "scheduled and performed as a screening procedure" (required specialist consultation, bowel-prep medication, anesthesia, polyp removal and pathology on a polyp biopsy) appears in the background paragraph above Q7, not inside it. Q7's own answer says the follow-up colonoscopy is integral to the screening. Whether a plan applies the integral-items list to a follow-up colonoscopy line by line is a question for member services, and the answer belongs in writing. The out-of-network layers, such as an anesthesiologist who is not in the plan's network at an in-network facility, fall under the separate protections described in the guide to balance billing under the No Surprises Act.

When the first test does not count

Medicare's follow-on route starts with the words "Medicare covered." The colonoscopy is screening only when the stool or blood test before it was itself a covered screening test. A positive result from a test Medicare would not have covered as a screening does not make the colonoscopy a screening, and the colonoscopy falls back to the ordinary diagnostic rules. The conditions below come from Medicare.gov's coverage pages, the regulation and the National Coverage Determination.

Sources: Medicare.gov pages for fecal occult blood tests, multi-target stool DNA tests and blood-based biomarker tests for colorectal cancer screening; 42 CFR 410.37(c); NCD 210.3 version effective June 8, 2026 (implementation January 4, 2027). Checked November 3, 2026. Original Medicare rules; a Medicare Advantage or private plan states its own.

Each condition decides a bill. Frequency decides it first: a second stool DNA test inside the three-year window is not a covered screening, and a positive result on it does not start a screening chain. Symptoms decide it next. Medicare.gov lists a positive guaiac or immunochemical test among the findings that rule out the stool DNA screening test, so a Cologuard ordered after a positive immunochemical test sits outside the screening benefit as the page words it. Risk history decides it last. A person with a personal history of adenomatous polyps is not "average risk" on these pages, so a stool test for that person is not a covered average-risk screening. A colonoscopy for a person at high risk has its own screening code, G0105, with a 24-month interval under 42 CFR 410.37(g)(2).

These conditions describe how the claim will be classified, not what any person's health situation calls for. A test ordered for symptoms is a diagnostic test; the statement that follows it is priced under diagnostic rules. The billing consequence is large, because the Part B deductible of $283.00 and 20 percent coinsurance then apply to the colonoscopy, and a hospital outpatient department adds its own copayment. The worked bills below show the size of that swing.

The same logic holds for private plans in a looser form. Q7 speaks of a positive "screening test" and of "individuals described in the USPSTF recommendation," so a stool test that was ordered because of a symptom is not within the sentence, and a plan may classify the colonoscopy that follows it as diagnostic. The label on the first order, and the diagnosis code on the first claim, are therefore worth knowing before the colonoscopy is scheduled.

Medicare coinsurance steps down to zero

For a Medicare patient whose follow-on colonoscopy involves removing tissue, the cost sharing is not the usual 20 percent. Section 1833(dd) of the Social Security Act, in the version current through Public Law 119-136, sets a special rule for these tests when they are furnished in a year from 2022 through 2029 and defines the "specified percent" of the payment amount that Medicare pays: "(A) for 2022, 80 percent; (B) for 2023 through 2026, 85 percent; and (C) for 2027 through 2029, 90 percent." The patient's coinsurance is the remainder. The manual puts it in coinsurance terms and adds the year 2030: for dates of service in 2023 through 2026 the claim carries a reduced coinsurance of 15 percent, for 2027 through 2029 it carries 10 percent, and "For dates of service on or after January 1, 2030, contractors shall continue to waive deductible and shall waive coinsurance for all procedure codes that meet the requirements stated above and are performed on that date of service and billed on the same claim."

The table applies the schedule to two procedures, using the 2026 amounts so that only the percentage changes. The physician amount is the 2026 physician fee schedule amount for the facility setting in Michigan Locality 01 (Detroit), built from the October 2026 relative value file with the work, practice expense and malpractice indices of 1.000, 0.965 and 1.686 and the $33.4009 conversion factor. The facility amount is the national unadjusted hospital outpatient payment rate from the October 2026 Addendum B, APC 5312 for both procedures.

Source: CMS PFS RVU26D (PPRRVU2026_Oct_nonQPP, released 08/26/2026) and GPCI2026, Michigan Locality 01; October 2026 OPPS Addendum B; 42 U.S.C. 1395l(dd); Claims Processing Manual chapter 18, section 60.1.1. Each share is the percentage times the approved amount for that layer, rounded to the cent on its own; the "both shares" column is the sum of the two shares. The 2027 and 2030 rows hold the 2026 amounts fixed on purpose. Checked November 3, 2026. Medicare anchors, not your bill.

On a colonoscopy with lesion removal in a hospital outpatient department, the coinsurance in 2026 is therefore $218.35: $34.97 on the physician claim and $183.38 on the facility claim. If the same procedure with the same amounts happened in 2027, it would be $145.57, and in 2030, nothing. The deductible is waived throughout. The dollar amounts of later years are not published yet: the physician and hospital payment rates are reset each year, and the CY2027 physician fee schedule proposed rule (Federal Register, July 16, 2026) does not mention 42 CFR 410.37 or a follow-on colonoscopy, so the percentages above are the schedule as it now stands and only the dollar bases are open.

The date that counts is the date of service, not the date of the stool test or the date of the statement. A positive Cologuard result in December 2026 followed by a colonoscopy in January 2027 puts the colonoscopy in the 10 percent year.

Two limits keep the table honest. It prices hospital outpatient departments only. Medicare.gov says the 15 percent facility coinsurance applies in an ambulatory surgical center as well, but the surgery center payment rates are not in the tables. The amounts are for the procedure claims only. Any pathology on the removed tissue is a separate claim whose treatment under this schedule is not stated in the sources used here, so it is left to the pathology bill guide and the question and answer on polyp pathology in the preventive care bill guide.

Five Medicare bills worked for 2026

The rows below price five follow-up situations for Original Medicare, with a hospital outpatient department, a provider that accepts assignment, Detroit physician amounts and national unadjusted facility rates. The first three rows are the screening route, where the stool test line is $0 because Medicare.gov lists $0 for covered clinical laboratory services and for the covered stool tests. The last two show the same procedures when the first test was not a covered screening; that test's own line follows whatever rule applies to it and is not priced here. In those two rows the Part B deductible of $283.00 is stated as already met so that only the 20 percent shows.

Source: CMS PFS RVU26D and GPCI2026 (Michigan Locality 01, facility setting); October 2026 OPPS Addendum B (APC 5311 and 5312; the 20 percent facility shares are the file's minimum unadjusted copayments); Medicare.gov coverage and costs pages. Checked November 3, 2026. Medicare anchors, not your bill.

In the first row a colonoscopy with nothing removed costs the patient $0 on both claims. The second and third rows show that tissue removal moves the bill only from zero to a few hundred dollars, and that the physician share is the smaller part. For lesion removal, the facility share of $183.38 is $148.41 larger than the physician share of $34.97, because the facility rate is more than five times the physician amount.

The last two rows are the bill that causes calls to the billing office. Without the screening label, a colonoscopy where nothing is removed costs $224.52 in this example, and one that removes a lesion costs $291.15. Set the lesion-removal rows against each other: the screening route is $218.35 and the diagnostic route is $291.15, which is $72.80 apart. The label matters most when nothing is removed, where it is the whole $224.52. The deductible is a further layer on the diagnostic route only. If the $283.00 is not yet met, the first claims processed absorb it, and the order in which the physician and hospital claims are processed changes which statement shows the larger balance, as the radiologist bill guide works through for a scan.

A hospital outpatient department's copayment for a single service cannot exceed the Part A hospital stay deductible in most cases, which Medicare.gov lists at $1,736.00 for each benefit period in 2026. None of the facility shares above comes near that ceiling. The hospital layer is explained in the facility fee guide, and the colonoscopy price pages show the same codes as colonoscopy and colonoscopy with biopsy anchors.

Codes and modifiers on the claim

On a Medicare claim the route is chosen by a handful of codes. The meanings below come from chapter 18 of the Claims Processing Manual. The table is a decoder for an itemized statement or a Medicare Summary Notice, so a person can see whether the claim was built on the screening route.

Source: CMS Medicare Claims Processing Manual, chapter 18, sections 60, 60.1, 60.1.1 and 60.2 (Rev. 13709, issued 04-02-26; section 60.1.1 text Rev. 12299). Checked November 3, 2026. Original Medicare coding; a private plan's claim system may use other markers.

Reading the table against a statement gives a quick sorting rule. A colonoscopy line that shows 45378 with no PT and no screening code is a diagnostic claim, and it carries the full $283.00 deductible and 20 percent unless the claim is corrected. A line that shows G0121 or G0105 without KX after a stool test is a screening claim without the follow-on marker, and the frequency edit that compares the date with the last screening colonoscopy may reject it. The manual's older note on the 25 percent coinsurance for screening colonoscopies in ambulatory surgical centers and non-OPPS hospitals is superseded by the same section's statement that, for dates of service from January 1, 2011, coinsurance and deductible do not apply to screening colonoscopies.

Private plans do not have to use Medicare's markers. The January 2022 federal FAQ does not prescribe a modifier. A later set of federal FAQs, Part 68 of October 21, 2024, says that when an in-network provider's claim identifies a service as preventive using industry-standard coding practices, such as CPT modifier 33 or a screening diagnosis code, plans should cover it without cost sharing unless the plan has individualized information showing the service was not preventive; its first example is a screening colonoscopy with polyp removal that a plan wrongly processed as therapeutic. A plan's claim system may still use a diagnosis code, a modifier or a benefit table of its own. The question to ask a billing office stays the same on either side of that line: what did you submit, and did the claim say the colonoscopy followed a positive stool test?

Sedation and anesthesia on the same date

The sedation or anesthesia bill follows the same fork, and the manual words it separately. For anesthesia, section 60.1.1 says services "furnished in conjunction with and in support of a screening colonoscopy are reported with CPT code 00812 and coinsurance and deductible are waived. When a screening colonoscopy becomes a diagnostic colonoscopy, anesthesia services are reported with CPT code 00811 and with the -PT modifier; and the deductible is waived." The next sentences of the section add that before January 1, 2022 the beneficiary "was liable for the full applicable coinsurance" when a screening became diagnostic, and then introduce the reduced coinsurance schedule described above.

For moderate sedation, the text reads: "Coinsurance and deductible are waived for moderate sedation services (reported with G0500 or 99153) when furnished in conjunction with and in support of a screening colonoscopy service and when reported with modifier -33. When a screening colonoscopy becomes a diagnostic colonoscopy, moderate sedation services (G0500 or 99153) are reported with only the -PT modifier; only the deductible is waived."

Those two passages are worded differently from the schedule sentence quoted earlier, which applies the reduced coinsurance to "all procedure codes" that meet the stated requirements and are billed on the same claim. When a sedation or anesthesia line shows a larger share than the colonoscopy lines on a Medicare Summary Notice, the billing office can say in writing which sentence the claim followed. The arithmetic of an anesthesia charge, base units plus time units times a conversion factor, is in the anesthesia bill guide, and that guide uses colonoscopy as one of its worked examples.

For a private plan, the integral-items list from the FAQ background is the closest federal statement: anesthesia services performed in connection with a preventive colonoscopy are among the items for which cost sharing may not be imposed when the colonoscopy is scheduled and performed as a screening. Whether the plan applies that to a follow-up colonoscopy is the same member-services question as for the other items.

A private-plan bill worked two ways

Commercial allowed amounts are not published, so this example uses invented round numbers and no price from any source. Suppose a plan member has $1,000.00 of the deductible still unmet, 20 percent coinsurance after it, and no out-of-pocket maximum reached. Three claims come from one episode: the stool test, the hospital's facility claim for a colonoscopy with lesion removal, and the gastroenterologist's claim. The invented allowed amounts are $400.00, $1,500.00 and $300.00. They are not Medicare rates and not commercial prices, and the three lines are never added into one allowed amount.

Invented inputs for arithmetic only: $1,000.00 deductible remaining, 20 percent coinsurance after it, claims processed in the order stool test, facility, physician. Not a price list and not drawn from any rate file. Computed and checked November 3, 2026.

In the middle column the stool test is processed correctly and only the colonoscopy lines are mislabeled. The facility claim absorbs the whole $1,000.00 deductible and then 20 percent of the remaining $500.00, for $1,100.00, and the physician claim asks 20 percent of $300.00, or $60.00. The patient shares sum to $1,160.00. In the right-hand column the stool test is mislabeled too. It absorbs $400.00 of the deductible first, the facility claim absorbs the remaining $600.00 and 20 percent of the rest, and the shares sum to $1,240.00. The order is an assumption stated for the example. A different order would move dollars between statements and leave the amount owed where the deductible and coinsurance put it.

The first column is the processing the federal FAQ calls for, and the gap to either of the others is the amount in dispute. A member who finds the middle or right-hand pattern on an explanation of benefits should start from the itemized statement, which carries the codes that the explanation of benefits leaves out. The guide to reading an explanation of benefits shows where each line and its patient share appear, and the itemized bill check puts the facility and physician statements side by side and flags a diagnostic code where a screening code was expected. The questions for each office, and the appeal path if the plan keeps the original processing, are in the next section. For a self-pay patient with no plan involved, none of this applies, and the first step is asking each office for a price in writing before the service.

What to ask each billing office

The same four facts decide every layer, so the same four questions work with every office, in this order. Start with the laboratory that ran the stool or blood test: which code did you bill, and was the order marked as a screening? The test's code and the diagnosis on the order are what a later colonoscopy claim is measured against. Ask the ordering practice for the date of the result, because the follow-on route depends on the result being positive and on the test being a covered screening.

Then ask the scheduler for the colonoscopy: will this be billed as a follow-up to a positive stool test, and what is the code that will go on the claim? On Original Medicare the answer should include a screening colonoscopy code with the KX modifier. For a private plan the answer should say the claim will be submitted as preventive or screening, with the date of the positive test. A scheduler who says the visit "will be diagnostic" has told you the label before the procedure. Whether that label is right depends on whether the first test was a covered screening, so the question to follow with is why.

Ask the facility whether tissue removal changes its billing and what the share would be. For Original Medicare in 2026 the answer should be 15 percent of the facility amount and no deductible; for a private plan, none of it. Ask the anesthesia group the same question, because it bills on its own. Ask for each answer by email or patient portal message where possible, so that a later correction starts from a record. The guide to asking for a cash price has wording for the case in which no coverage applies.

The last question is for the plan or the Medicare contractor: if the claim is processed differently from what the office said, what is the review path and the deadline? If the plan keeps the original processing, the written appeal in the guide to appealing a denial is the next step, and the quoted text of Q7 above is the federal rule to cite. Filing deadlines are in the guide on bills that arrive months later. A balance that is in dispute and not yet resolved is a reason to ask the billing office to hold it, which is the topic of the collections guide.

Follow-up colonoscopy billing questions

Fee files, rules and notices cited

• CMS, Clinical Laboratory Fee Schedule file 26CLABQ4 (PUF_CLFS_CY2026_Q4V1; codes 81528, 0464U, 82274, G0328, 82270 and G0327, with the read-me describing the indicator column). Checked November 3, 2026.
• CMS, Physician Fee Schedule relative value file RVU26D (PPRRVU2026_Oct_nonQPP, released 08/26/2026) with GPCI2026, Michigan Locality 01, for codes G0121, 45378, 45380 and 45385 in the facility setting, with the $33.4009 conversion factor. Checked November 3, 2026.
• CMS, October 2026 OPPS Addendum B (file dated 10.14.26): payment rates and minimum unadjusted copayments for APC 5311 and 5312. Ambulatory surgery center amounts are not in the tables. Checked November 3, 2026.
• U.S. Departments of Labor, Health and Human Services and the Treasury, FAQs About Affordable Care Act Implementation Part 51 (January 10, 2022), the section Coverage of Colonoscopies Pursuant to USPSTF Recommendations, Q7 and Q8, from the Department of Labor's FAQ index. Part 51 is the latest document located that addresses a follow-up colonoscopy after a positive stool-based test; FAQs About Affordable Care Act and Women's Health and Cancer Rights Act Implementation Part 68 (October 21, 2024), Q2 and Q6 Example 1, is the later document on how a plan should treat a claim coded as a screening colonoscopy with polyp removal. Checked November 3, 2026.
• eCFR, 45 CFR 147.130 (coverage of preventive health services) and 42 CFR 410.37 (colorectal cancer screening tests), versions dated October 28, 2026. Checked November 3, 2026.
• Office of the Law Revision Counsel, 42 U.S.C. 1395l (payment of benefits), the release current through Public Law 119-136 (October 22, 2026): subsection (a)(1)(Y), the sentence on colorectal cancer screening tests for services furnished on or after January 1, 2022 (the "third sentence" of subsection (a) in the words of (dd)(1)), and subsection (dd). Checked November 3, 2026.
• CMS, Medicare Claims Processing Manual, chapter 18, Preventive and Screening Services (Rev. 13709, issued 04-02-26), sections 60 to 60.2. Checked November 3, 2026.
• CMS, National Coverage Determination 210.3, Colorectal Cancer Screening Tests, version effective June 8, 2026 and the revision history, with Transmittal 13921 (CR14581, August 27, 2026). Checked November 3, 2026.
• U.S. Preventive Services Task Force, Colorectal Cancer: Screening, final recommendation statement (May 18, 2021), the current statement on the Task Force site. Checked November 3, 2026.
• Medicare.gov, Colonoscopies (screening), Multi-target stool DNA tests, Fecal occult blood tests, Blood-based biomarker tests and Medicare costs (2026 Part B deductible of $283.00, Part A deductible of $1,736.00). Checked November 3, 2026.
• Federal Register, CY 2027 Payment Policies Under the Physician Fee Schedule proposed rule (July 16, 2026). Checked November 3, 2026.

General billing information, not medical, legal or insurance advice. Medicare anchors and fee-file rates are not your bill, and a laboratory's, hospital's or physician's own charges and a plan's allowed amounts can differ from them. Medicare Advantage, Medigap and Medicaid rules are not covered here. Confirm your price in writing before service.